Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
Asad Makhani,1 Miriam Thake,2 William Gibson1 1University of Alberta, Division of Geriatric Medicine, Edmonton, Alberta, Canada; 2Great Western Hospitals NHS Foundation Trust, Swindon SN3 6BB, UKCorrespondence: William GibsonUniversity of Alberta, Division of Geriatric Medicine, 1-198 Clinical Scien...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b65e6b143e1944148ed126181816220e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Asad Makhani,1 Miriam Thake,2 William Gibson1 1University of Alberta, Division of Geriatric Medicine, Edmonton, Alberta, Canada; 2Great Western Hospitals NHS Foundation Trust, Swindon SN3 6BB, UKCorrespondence: William GibsonUniversity of Alberta, Division of Geriatric Medicine, 1-198 Clinical Sciences Building, 11350 83 Ave, Edmonton, Alberta Tel +1 780 248 1969Email wgibson@ualberta.caAbstract: Lower urinary tract symptoms, including urgency, urgency incontinence, frequency, and nocturia, are highly prevalent in older adults and are associated with significant morbidity and impairment in quality of life. When conservative measures such as bladder training fail to improve symptoms, pharmacological management is recommended by national and international guidelines. Mirabegron, an agonist of the β 3 adrenergic receptor, demonstrates similar efficacy to the anticholinergic drugs without the risk of anticholinergic effects, but experience and evidence in the very elderly population are limited. This narrative review examines the current evidence base for mirabegron in very elderly adults.Keywords: overactive bladder, mirabegron, elderly, ageing, anticholinergic, urinary incontinence |
|---|